The switch to virtual meetings has created challenges for many business relationships, none perhaps more so than between the US Food and Drug Administration and drug sponsors. In particular, sponsors need to adjust their approach to account for two specific issues:
That’s the advice of consultants who spoke during a recent webinar convened by Informa Pharma Intelligence. [Editor’s note: Replays of...





